Ask AI

Strategies for Adjuvant Treatment in HER2+ Early-Stage Breast Cancer

These slides and accompanying video module review evolving evidence and clinical decision-making for adjuvant therapy in patients with HER2-positive early breast cancer (EBC), with a focus on tailoring treatment according to pathologic response, baseline stage, residual disease burden, and recurrence risk. Key data include long-term outcomes from APHINITY and KATHERINE, emerging evidence from DESTINY-Breast05 comparing adjuvant trastuzumab deruxtecan (T-DXd) with trastuzumab emtansine (T-DM1) in patients with high-risk residual disease, and considerations related to CNS recurrence, treatment toxicity, and reassessment of HER2 status after neoadjuvant therapy. The slides also address extended adjuvant neratinib, endocrine therapy selection in HR-positive/HER2-positive disease, and the evolving choice between neoadjuvant and adjuvant T-DXd, highlighting how these data may inform individualized treatment selection and risk-adapted management in clinical practice.

Adjuvant Tx in HER2 EBC

Activity Information

Released: October 13, 2026